Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.
Centonze, D., Furlan, R., Gasperini, C., Salvetti, M., Battistini, L. (2008). Early relapses after the first dose of natalizumab in active multiple sclerosis patients. MULTIPLE SCLEROSIS, 14(8), 1137-1138 [10.1177/1352458508092810].
Early relapses after the first dose of natalizumab in active multiple sclerosis patients
CENTONZE, DIEGO;
2008-09-01
Abstract
Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.